MP03-14 RETROPERITONEAL LAPAROSCOPIC COOL-TIP RADIOFREQUENCY ABLATION OF ADRENOCORTICAL ADENOMA WITH CUSHING SYNDROME

Abstract

You have accessJournal of UrologyAdrenal1 Apr 2018MP03-14 RETROPERITONEAL LAPAROSCOPIC COOL-TIP RADIOFREQUENCY ABLATION OF ADRENOCORTICAL ADENOMA WITH CUSHING SYNDROME Linfang Yao, Shiwei Zhang, Xiaozhi Zhao, Rong Yang, and Hongqian Guo Linfang YaoLinfang Yao More articles by this author , Shiwei ZhangShiwei Zhang More articles by this author , Xiaozhi ZhaoXiaozhi Zhao More articles by this author , Rong YangRong Yang More articles by this author , and Hongqian GuoHongqian Guo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.3057AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To evaluate the feasibility, safety, and therapeutic effects of retroperitoneoscopic-guided cool-tip radiofrequency ablation (RCRFA) used for the treatment of adrenocortical adenoma with Cushing syndrome. METHODS From May 2006 to May 2009, 12 female patients with adrenocortical adenoma and Cushing syndrome underwent RCRFA. Ten tumors were in the left adrenal gland and two tumors were in the right, with a mean tumor size of 2.8+0.5cm (range 2.0 to 3.5). Technical success was defined as disappearance of tumor enhancement on contrast-enhanced computed tomography imaging acquired within 4 week after RCRFA. Clinical success was defined as improvement in serum cortisol and adrenocorticotropic hormone (ACTH) values and symptoms at the end of follow-up. RESULTS Tumor enhancement disappeared after initial RCRFA in all patients (technical success rate 100%) one month later. Both the serum cortisol and ACTH levels returned to normal and the symptoms related to Cushing syndrome had disappeared. Every patient was followed up for more than 6 years (mean 85.2±11.2 months). There was no evidence of residual or recurrent lesion postoperatively. All tumors showed involution (1.5+0.6cm) at the end of the study. No major complications occurred related to the procedures. CONCLUSIONS Using RCRFA for adrenocortical adenoma with Cushing syndrome is a feasible, safe, and promising treatment method in selected patients. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e27-e28 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Linfang Yao More articles by this author Shiwei Zhang More articles by this author Xiaozhi Zhao More articles by this author Rong Yang More articles by this author Hongqian Guo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...